While progress continues to be made in cancer treatment, some cancers may return or become resistant to existing therapies. For patients who have already received several treatments, these diseases can be especially challenging.
While many treatments are effective, some cancers can return or become resistant to therapy. In these cases, patients may go through several treatments without achieving a lasting response.
Plain Languange Summaries of Journal Articles
To help make recent cancer research easier to understand, the summaries below provide plain language explanations of scientific journal articles. Each summary is reviewed by independent medical experts. Please consult your healthcare professional if you have any questions.
Disclaimer: These summaries are not intended to provide medical advice or endorse any treatment.
Learn more about our Clinical Trials
These clinical trials are intended to study loncastuximab tesirine for investigational uses that are not yet approved by the FDA.
LOTIS-5
[402-311] – A Phase 3 Randomized Study of Loncastuximab Tesirine-lpyl Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
LOTIS-7
A Phase 1b, Open-label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine-lpyl in Combination With Other Anticancer Agents in Patients with Relapsed or Refractory B-cell Lineage Non-Hodgkin Lymphoma (B-NHL)